Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Lymphoma" returned 9 results:

A Randomized, Double-Blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Principal Investigator(s): Joshua Brody

A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies
Principal Investigator(s): Dr. Joshua Brody

“Protocol 2603: Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of off-the-shelf ex vivo expanded cryospreserved cord blood progenitor cells in patients with hematologic malignancies”
Principal Investigator(s): Dr. Alla Keyzner

A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Principal Investigator(s): Amir Steinberg, MD

A Phase I/II Study of Intratumoral Injection of rhuFlt3L/CDX-301 and Poly-ICLC in Combination with Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas
Principal Investigator(s): Joshua Brody

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
Principal Investigator(s): Amir Steinberg, MD

A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
Principal Investigator(s): Dr. Joshua Brody

BMT CTN 1101: A multi-center, phase 3, randomized trial of reduced intensity conditioning and transplantation of double unrelated umbilical cord blood versus HLA-Haploidentical related bone marrow for patients with hematological malignancies
Principal Investigator(s): Adriana Malone

Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Principal Investigator(s): Dr. Samir Parekh